No Data
No Data
$1000 Invested In Illumina 20 Years Ago Would Be Worth This Much Today
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs
Illumina Unveils Largest Omics Solutions Portfolio Including Genomics, Spatial, Single Cell, CRISPR Technologies; Introduces Multimodal Data Analysis Platform
Illumina Transforms Multiomic Research With New Technologies to Unlock Deeper Understanding of Biology
BofA Securities Maintains Illumina(ILMN.US) With Sell Rating, Maintains Target Price $90
Express News | Illumina and Broad Clinical Labs Usher in New Era of Drug Discovery With Collaboration to Rapidly Scale Single-Cell Solutions